| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. 
|
|
Today’s Big NewsMay 5, 2025 |
|
These studies reveal a drug’s active free fraction, which impacts safety and efficacy. QPS experts explain the methods to determine plasma protein binding. Download the QPS white paper: Plasma Protein Binding 
|
|
| By Zoey Becker Last year's $50 billion increase in net drug spending marked a period of "historic growth" that was only surpassed by 2021's COVID-19 vaccine launches, according to a new report from life sciences intelligence firm IQVIA. |
|
|
|
By Darren Incorvaia Johnson & Johnson bought the full rights to a rare disease gene therapy a few years ago, but now the Big Pharma may be feeling buyer’s remorse. The treatment failed to improve the vision-guided mobility of patients with the eye disease X-linked retinitis pigmentosa (XLRP) in a phase 3 trial, the company announced in a May 2 release. |
By Conor Hale The Jewel wearable cardioverter defibrillator system can be worn during sleep and showers, with its low-profile and water-resistant design. |
By Andrea Park After a 2024 in which AbbVie’s Skyrizi boasted the highest TV drug ad spending outlay on seven of our monthly roundups—and took second place in four more—the immunology med has seen that dominance slip in 2025. |
|
Thursday, May 15, 2025 | 12pm ET / 9am PT Join this webinar for a deep dive into today’s biotech investment climate and practical strategies to navigate commercialization when pharma partnerships are delayed or uncertain. 
|
|
By Zoey Becker Both companies are working on workforce optimization efforts, prompting a headcount reduction of 24 at Mammoth and sweeping changes across Unity's workforce. |
By Eric Sagonowsky BioNTech is making plans to debut on the commercial oncology scene. Part of that effort involves mapping out a larger manufacturing footprint. |
By Gabrielle Masson Deerfield Management has unveiled the third installment of its healthcare innovations fund, earmarking more than $600 million for promising therapeutics and technologies. |
By Andrea Park A little over a month after announcing her departure from Moderna, Kate Cronin has begun her “next adventure.” |
By Darren Incorvaia Vertex Pharmaceuticals is no longer developing adeno-associated viruses as gene therapy vectors, a company spokesperson confirmed with Fierce Biotech. |
By Kevin Dunleavy After failing to resolve tens of thousands of talc lawsuits with three unsuccessful bankruptcy attempts, Johnson & Johnson is resuscitating another strategy—seeking to discredit an expert witness who has supported claimants who say that the company’s talc products caused their cancer. |
By Andrea Park To help spread the message that managing Type 2 diabetes “doesn’t have to be a solo act,” Eli Lilly, fittingly, is assembling a star-studded team. |
By Fraiser Kansteiner Recursion is “deprioritizing” three clinical-stage programs, pausing another and winding down a single preclinical program in an undisclosed target, the company revealed in its first-quarter financial results Monday. The biotech said it will specifically look to either discontinue the programs or pass them on via partnerships. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," hear how the founders of ElevAAte are turning shared East Asian American experiences into collective power for the next generation of biopharma leaders. |
|
|---|
|
|
|
Tuesday, May 20, 2025 | 11am ET / 8am PT This webinar will feature industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Register today to learn more. 
|
|
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. - Learn how the SpyTag/SpyCatcher protein ligation system was engineered into SpyLock technology to streamline bispecific antibody generation
- Discover how SpyLock technology reduces workload by enabling rapid bispecific assembly and accelerating candidate selection
- Explore a real-world case study of constructing anti-PD1/PD-L1 bispecific antibodies using SpyLock for functional screening.
Sponsored by: Bio-Rad |
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| |
|
